Form 4: Crinetics Officer Sells Shares After Option Exercise

Crinetics Pharmaceuticals' Chief Medical and Development Officer, Dana Pizzuti, exercised stock options and subsequently sold an equal number of shares under a pre-arranged 10b5-1 trading plan.

Summary

• Dana Pizzuti, Chief Medical and Development Officer of Crinetics Pharmaceuticals, Inc., exercised options to acquire 5,000 shares of common stock at $16.89 per share on December 1, 2025.
• Concurrently, Pizzuti sold 5,000 shares of common stock in open market transactions at a volume-weighted average price of $45.02 per share on the same date, with sale prices ranging from $44.59 to $45.51.
• The sale was executed automatically pursuant to a Rule 10b5-1 trading plan adopted by the Reporting Person on May 21, 2025.
• Following these transactions, Pizzuti beneficially owns 66,837 shares of common stock and 69,042 stock options.
• The exercised option was part of a grant where 25% vested on September 30, 2023, with the remainder vesting monthly over 36 installments, contingent on continued employment.

Sentiment

Score: 6

Explanation: Neutral to slightly positive. While an insider sale can be seen negatively, the transaction was pre-planned under a 10b5-1 plan, indicating a routine liquidity event rather than a bearish signal. The significant profit from the option exercise is a positive for the executive.

Positives

• The officer realized a significant personal gain by exercising options at $16.89 per share and selling at an average of $45.02 per share.
• The transaction was conducted under a pre-established Rule 10b5-1 trading plan, indicating a structured approach to managing equity and reducing concerns about opportunistic trading.

Negatives

• An insider selling shares, even under a 10b5-1 plan, can sometimes be perceived negatively by the market as it reduces their direct equity stake.

Future Outlook

NA

Industry Context

NA

Stakeholder Impact

• Shareholders: May view the insider sale with slight caution, though the 10b5-1 plan mitigates concerns. The officer's continued significant equity holdings (options and shares) still align interests.
• Employees: No direct impact mentioned, but the vesting schedule highlights standard equity compensation practices.

Key Dates

Recommendation

This Form 4 filing details a routine insider transaction involving an option exercise and subsequent sale under a pre-established 10b5-1 trading plan. Such transactions are typically for personal financial planning and liquidity rather than a signal of future company performance. The officer retains a substantial equity stake, aligning their interests with shareholders. Without additional fundamental news, this filing alone does not warrant a change in investment thesis, thus a 'hold' recommendation is appropriate.

Keywords

Crinetics Pharmaceuticals, CRNX, Insider Trading, Form 4, Stock Option Exercise, Share Sale, Dana Pizzuti, 10b5-1 Plan, Biotechnology, Pharmaceuticals